Vitamin D supplementation and clinical outcomes in COVID-19: a systematic review and meta-analysis
Pal R, Banerjee M, Bhadada SK, Shetty AJ, Singh B, Vyas A
Journal of endocrinological investigation · 94 citas
Cómo se estudió
- Diseño
- Revisión sistemática (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2021-06-24 · J Endocrinol Invest · vol. 45 · número 1 · págs. 53–68
- Editorial
- Springer Science+Business Media
- Citado
- 127 citas · más que el 98% de estudios similares · 6.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 55 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Vitamin D Research Studies · COVID-19 Clinical Research Studies · SARS-CoV-2 and COVID-19 Research
- Palabras clave
- vitamin D supplementation, COVID-19 pandemic, intensive care unit admission, mortality, clinical outcomes
- MeSH
- humans, vitamin d deficiency, vitamin d, treatment outcome, odds ratio, comorbidity, dietary supplements, intensive care units, covid-19, sars-cov-2, covid-19 drug treatment
6 autores
- Rimesh Pal🇮🇳Post Graduate Institute of Medical Education and Research
- Mainak Banerjee🇮🇳Institute of Post Graduate Medical Education and Research
- Sanjay Kumar Bhadada🇮🇳 · autor de correspondenciaPost Graduate Institute of Medical Education and Research
- Akshay Shetty🇮🇳Post Graduate Institute of Medical Education and Research
- Birgurman Singh🇮🇳Government Medical College
- A. Vyas🇮🇳Rabindranath Tagore Medical College
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
To provide a precise summary and collate the hitherto available clinical evidence on the effect of vitamin D supplementation on clinical outcomes in COVID-19 patients.
Methods
PubMed/MEDLINE, Scopus, and Web of Science databases were systematically searched using appropriate keywords till June 8, 2021, to identify observational studies and randomized controlled trials (RCTs) reporting adverse clinical outcomes (ICU admission and/or mortality) in COVID-19 patients receiving vitamin D supplementation vs. those not receiving the same. Both prior use and use of vitamin D after COVID-19 diagnosis were considered. Unadjusted/adjusted pooled odds ratio (OR) with 95% confidence intervals (CI) were calculated (PROSPERO registration number CRD42021248488).
Results
We identified 13 studies (10 observational, 3 RCTs) pooling data retrieved from 2933 COVID-19 patients. Pooled analysis of unadjusted data showed that vitamin D use in COVID-19 was significantly associated with reduced ICU admission/mortality (OR 0.41, 95% CI: 0.20, 0.81, p = 0.01, I2 = 66%, random-effects model). Similarly, on pooling adjusted risk estimates, vitamin D was also found to reduce the risk of adverse outcomes (pooled OR 0.27, 95% CI: 0.08, 0.91, p = 0.03, I2 = 80%, random-effects model). Subgroup analysis showed that vitamin D supplementation was associated with improved clinical outcomes only in patients receiving the drug post-COVID-19 diagnosis and not in those who had received vitamin D before diagnosis.
Conclusions
Vitamin D supplementation might be associated with improved clinical outcomes, especially when administered after the diagnosis of COVID-19. However, issues regarding the appropriate dose, duration, and mode of administration of vitamin D remain unanswered and need further research.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.